Harrow Health
Imprimis Pharmaceuticals (Nasdaq: IMMY) is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at affordable prices..
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | N/A | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 58 % | 29 % | 34 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 8 % | 23 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (46 %) | 34 % | 15 % | 10 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Harrow, Inc., previously known as Imprimis Pharmaceuticals and Harrow Health, is a publicly-traded ophthalmic pharmaceutical company headquartered in Nashville, Tennessee. Founded in 2012 by Mark L. Baum, the company began generating revenue in April 2014 through its ImprimisRx brand. Baum, a lawyer by training with a background in the HIV-focused pharmacy sector and private investment, has been a vocal advocate for competitive drug pricing. This philosophy shaped the company's initial business model, which centered on providing affordable alternatives to high-priced, off-patent medicines.
The company's core business operates through two primary channels. Its subsidiary, ImprimisRx, is a significant national compounding pharmacy that alters or combines existing drugs to create customized formulations for specific patient needs, particularly in ophthalmology. This allows Harrow to offer competitive options for drugs that may otherwise be controlled by a single manufacturer. Over time, Harrow has expanded its strategy to include a portfolio of FDA-approved branded products, making it a provider of both compounded and branded pharmaceuticals. Revenue is generated from the sale of these products to physicians, clinics, and hospitals, serving the U.S. ophthalmic market.
Harrow's product portfolio is extensive, covering surgical needs for cataract and glaucoma procedures, treatments for dry eye disease and infections, and other in-office ophthalmic therapies. The company has grown significantly through strategic acquisitions, purchasing the U.S. commercial rights to multiple FDA-approved ophthalmic products from companies like Novartis. These acquisitions include well-known treatments such as ILEVRO, NEVANAC, VIGAMOX, and TRIESENCE. Beyond its core operations, Harrow has a history of incubating new ventures, having founded and invested in companies like Eton Pharmaceuticals, Surface Ophthalmics, and Melt Pharmaceuticals, retaining equity stakes and royalty rights in some of their clinical-stage drug candidates.
Keywords: ophthalmic pharmaceuticals, compounding pharmacy, drug pricing, eyecare, surgical products, branded pharmaceuticals, FDA-approved drugs, Mark L. Baum, ImprimisRx, cataract surgery